The role of adipokines and insulin resistance in the pathogenesis of nonalcoholic fatty liver disease;Rola adipokin i insulinooporności w patogenezie niealkoholowej stłuszczeniowej choroby wa̧troby

Postepy Higieny i Medycyny Doswiadczalnej

Volumn 64, Issue , 2010, Pages 212-219

  Orlik, Bartłomiej ^a   Handzlik, Gabriela ^a   Olszanecka Glinianowicz, Magdalena ^a  

^a Uniwersytetu Medycznego w Katowicach ^*  (Poland)

Author keywords

Adipokines; Insulin resistance; NAFLD

Indexed keywords

ADIPOCYTOKINE;

FATTY LIVER; HUMAN; INSULIN RESISTANCE; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

ADIPOKINES; FATTY LIVER; HUMANS; INSULIN RESISTANCE;

EID: 77954750389     PISSN: 00325449     EISSN: 17322693     Source Type: Journal    
DOI: None     Document Type: Review

References (103)

1. Abiru S., Migita K., Maeda Y., Daikoku M., Ito M., Ohata K., Nagaoka S., Matsumoto T., Takii Y., Kusumoto K., Nakamura M., Komori A., Yano K., Yatsuhashi H., Eguchi K., Ishibashi H.: Serum cytokine and soluble cytokine receptor levels in patients with non-alcoholic steatohepatitis. Liver. Int., 2006;26:39-45
2. Aller R., de Luis D. A., Izaola O., Sagrado M. G., Conde R., Velasco M. C., Alvarez T., Pacheco D., González J. M.: Infuence of visfatin on histopathological changes of non-alcoholic fatty liver disease. Dig. Dis. Sci., 2009;54; 1772-1777
3. Anania F. A.: Adiponectin and alcoholic fatty liver: is it, after all, about what you eat? Hepatology, 2005;42:530-532 (Pubitemid 41233643)
4. Angulo P., Alba L. M., Petrovic L. M., Adams L. A., Lindor K. D., Jensen M. D.: Leptin, insulin resistance, and liver fibroosis in human nonalcoholic fatty liver disease. J. Hepatol., 2004;41:943-949 (Pubitemid 39575661)
5. Angulo P., Keach J. C., Batts K. P., Lindor K. D.: Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology, 1999;30:1356-1362
6. Bełtowski J.: Adiponectin and resistin - new hormones of white adipose tissue. Med. Sci. Monit., 2003;9: RA55-RA61 (Pubitemid 36330378)
7. Berg A. H., Combs T. P., Du X., Brownlee M., Scherer P. E.: The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat. Med., 2001;7:947-953 (Pubitemid 32756433)
8. Bernard S., Touzet S., Personne I., Lapras V., Bondon P. J., Berthezene F., Moulin P.: Association between microsomal triglyceride transfer protein gene polymorphism and the biological features of liver steatosis in patients with type II diabetes. Diabetologia, 2000;43:995-999 (Pubitemid 30655718)
9. Bertolani C., Sancho-Bru P., Failli P., Bataller R., Aleffi S., DeFranco R., Mazzinghi B., Romagnani P., Milani S., Ginés P., Colmenero J., Parola M., Gelmini S., Tarquini R., Laffi G., Pinzani M., Marra F.: Resistin as an intrahepatic cytokine: overexpression during chronic injury and induction of proinflammatory actions in hepatic stellate cells. Am. J. Pathol., 2006;169:2042-2053 (Pubitemid 351181964)
10. Bokarewa M., Nagaev I., Dahlberg L., Smith U., Tarkowski A.: Resistin, an adipokine with potent proinflammatory properties. J. Immunol., 2005;174:5789-5795 (Pubitemid 40593223)
11. Brun P., Castagliuolo I., Di Leo V., Buda A., Pinzani M., Palu G., Martines D.: Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis. Am. J. Physiol. Gastrointest. Liver Physiol., 2007;292:G518-G525
12. Bugianesi E., Pagotto U., Manini R., Vanni E., Gastaldelli A., de Iasio R., Gentilcore E., Natale S., Cassader M., Rizzetto M., Pasquali R., Marchesini G.: Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity. J. Clin. Endocrinol. Metab., 2005;90:3498-3504 (Pubitemid 41014319)
13. Cairns S. R., Peters T. J.: Biochemical analysis of hepatic lipid in alcoholic and diabetic and control subjects. Clin. Sci., 1983;65:645-652 (Pubitemid 13018313)
14. Chalasani N., Crabb D. W., Cummings O. W., Kwo P. Y., Asghar A., Pandya P. K., Considine R. V.: Does leptin play a role in the pathogenesis of human nonalcoholic steatohepatitis? Amer. J. Gastroenterol., 2003;98:2771-2776 (Pubitemid 38020122)
15. Chitturi S., Farrell G., Frost L., Kriketos A., Lin R., Fung C., Liddle C., Samarasinghe D., George J.: Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: a manifestation of lipotoxicity? Hepatology, 2002;36:403-409 (Pubitemid 34810360)
16. Cressman D. E., Greenbaum L. E., DeAngelis R. A., Ciliberto G., Furth E. E., Poli V., Taub R.: Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice. Science, 1996;274:1379-1383 (Pubitemid 26391463)
17. Dixon J. B., Bhathal P. S., O'Brien P. E.: Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibroosis in the severely obese. Gastroenterology, 2001;121:91-100 (Pubitemid 32591518)
18. Donnelly K. L., Smith C. I., Schwarzenberg S. J., Jessurun J., Boldt M. D., Parks E. J.: Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J. Clin. Invest., 2005;115:1343-1351 (Pubitemid 40629054)
19. El-Assal O., Hong F., Kim W. H., Radaeva S., Gao B.: IL-6-deficient mice are susceptible to ethanol-induced hepatic steatosis: IL-6 protects against ethanol-induced oxidative stress and mitochondrial permeability transition in the liver. Cell. Mol. Immunol., 2004;1:205-211
20. Farrell G. C.: Hepatic non-alcoholic steatosis. W: The Text Book of Hepatology: From basic science to clinical practice, 3rd edition. Red. Rodes J., Benhamou J. P., Blei A., Reichen J., Rizzetto M. Wiley-Blackwell, San Francisco, 2007;1195-1208
21. Feldstein A. E., Werneburg N. W., Canbay A., Guicciardi M. E., Bronk S. F., Rydzewski R., Burgart L. J., Gores G. J.: Free fatty acids promote hepatic lipotoxicity by stimulating TNF-aá expression via a lysosomal pathway. Hepatology, 2004;40:185-194 (Pubitemid 38868937)
22. Fukuhara A., Matsuda M., Nishizawa M., Segawa K., Tanaka M., Kishimoto K., Matsuki Y., Murakami M., Ichisaka T., Murakami H., Watanabe E., Takagi T., Akiyoshi M., Ohtsubo T., Kihara S., Yamashita S., Makishima M., Funahashi T., Yamanaka S., Hiramatsu R., Matsuzawa Y., Shimomura I.: Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science, 2005;307:426-430 (Pubitemid 40139988)
23. Golik A., Rubio A., Weintraub M., Byrne L.: Elevated serum liver enzymes in obesity: a dilemma during clinical trials. Int. J. Obes., 1991;15:797-801
24. Graham T. E., Yang Q., Blüher M., Hammarstedt A., Ciaraldi T. P., Henry R. R., Wason C. J., Oberbach A., Jansson P. A., Smith U., Kahn B. B.: Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N. Engl. J. Med., 2006;354:2552-2563 (Pubitemid 43882351)
25. Haukeland J. W., Damås J. K., Konopski Z., Løberg E. M., Haaland T., Goverud I., Torjesen P. A., Birkeland K., Bjøro K., Aukrust P.: Systemic infammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. J. Hepatol., 2006;44:1167-1174
26. Hotamisligil G. S., Shargill N. S., Spiegelman B. M.: Adipose expression of tumor necrosis factor-a: direct role in obesity-linked insulin resistance. Science, 1993;259:87-91 (Pubitemid 23036092)
27. Hui J. M., Hodge A., Farrell G. C., Kench J. G., Kriketos A., George J.: Beyond insulin resistance in NASH: TNF-α or adiponectin? Hepatology, 2004;40:46-54 (Pubitemid 38868922)
28. Ikejima K., Honda H., Yoshikawa M., Hirose M., Kitamura T., Takei Y., Sato N.: Leptin augments inflammatory and pro fibroogenic responses in the murine liver induced by hepatotoxic chemicals. Hepatology, 2001;34:288-297 (Pubitemid 32702342)
29. Ikejima K., Takei Y., Honda H., Hirose M., Yoshikawa M., Zhang Y. J., Lang T., Fukuda T., Yamashina S., Kitamura T., Sato N.: Leptin receptor-mediated signaling regulates hepatic fibroogenesis and remodeling of extracellular matrix in the rat. Gastroenterology, 2002;122:1399-1410 (Pubitemid 34465182)
30. Janowska J., Zahorska-Markiewicz B., Olszanecka-Glinianowicz M.: Relationship between serum resistin concentration and proinfammatory cytokines in obese women with impaired and normal glucose tolerance. Metabolism, 2006;55:1495-1499 (Pubitemid 44537347)
31. Jarrar M. H., Baranova A., Collantes R., Ranard B., Stepanova M., Bennett C., Fang Y., Elariny H., Goodman Z., Chandhoke V., Younossi Z. M.: Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment. Pharmacol. Ther., 2008;27:412-421
32. Jin X., Zimmers T. A., Perez E. A., Pierce R. H., Zhang Z., Koniaris L. G.: Paradoxical effects of short-and long-term interleukin-6 exposure on liver injury and repair. Hepatology, 2006;43:474-484
33. Kakuma T., Lee Y., Higa M., Wang Z., Pan W., Shimomura I., Unger R. H.: Leptin, troglitazone, and the expression of sterol regulatory element binding proteins in liver and pancreatic islets. Proc. Natl. Acad. Sci. USA, 2000;97:8536-8541 (Pubitemid 30639708)
34. Kamada Y., Matsumoto H., Tamura S., Fukushima J., Kiso S., Fukui K., Igura T., Maeda N., Kihara S., Funahashi T., Matsuzawa Y., Shimomura I., Hayashi N.: Hypoadiponectinemia accelerates hepatic tumor formation in a nonalcoholic steatohepatitis mouse model. J. Hepatol., 2007;47:556-564 (Pubitemid 47331742)
35. Kamada Y., Tamura S., Kiso S., Matsumoto H., Saji Y., Yoshida Y., Fukui K., Maeda N., Nishizawa H., Nagaretani H., Okamoto Y., Kihara S., Miyagawa J., Shinomura Y., Funahashi T., Matsuzawa Y: Enhanced carbon tetrachloride-induced liver fibroosis in mice lacking adiponectin. Gastroenterology, 2003;125:1796-1807 (Pubitemid 37500444)
36. Kaser S., Moschen A., Cayon A., Kaser A., Crespo J., Pons-Romero F., Ebenbichler C. F., Patsch J. R., Tilg H.: Adiponectin and its receptors in non-alcoholic steatohepatitis. Gut, 2005;54:117-121 (Pubitemid 40007229)
37. Kim J. K., Fillmore J. J., Chen Y., Yu C., Moore I. K., Pypaert M., Lutz E. P., Kako Y., Velez-Carrasco W., Goldberg I. J., Breslow J. L., Shulman G. I.: Tissue-specific overexpression of lipoprotein lipase causes tissue-specific insulin resistance. Proc. Natl. Acad. Sci. USA, 2001;98:7522-7527 (Pubitemid 32567981)
38. Lee R. G.: Nonalcoholic steatohepatitis: a study of 49 patients. Hum. Pathol., 1989;20:594-598 (Pubitemid 19164370)
39. Lee W. J., Wu C. S., Lin H., Lee I. T., Wu C. M., Tseng J. J., Chou M. M., Sheu W. H.: Visfatin-induced expression of infiammatory mediators in human endothelial cells throught the NF-κB pathway. Int. J. Obes., 2009;33:465-472
40. Li Z., Yang S., Lin H., Huang J., Watkins P. A., Moser A. B., Desimone C., Song X. Y., Diehl A. M.: Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology, 2003;37:343-350 (Pubitemid 36152533)
41. Lin H. Z., Yang S. Q., Chuckaree C., Kuhajda F., Ronnet G., Diehl A. M.: Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat. Med., 2000;6:998-1003
42. Liu H., Jones B. E., Bradham C., Czaja M. J.: Increased cytochrome P-450 2E1 expression sensitizes hepatocytes to c-Jun-mediated cell death from TNF-a. Am. J. Physiol. Gastrointest. Liver Physiol., 2002;282:G257-G266 (Pubitemid 34651682)
43. López-Bermejo A., Botas P., Funahashi T., Delgado E., Kihara S., Ricart W., Fernández-Real J. M.: Adiponectin, hepatocellular dysfunction and insulin sensitivity. Clin. Endocrinol., 2004;60:256-263 (Pubitemid 38200909)
44. Ma H., Gomez V., Lu L., Yang X., Wu X., Xiao S. Y.: Expression of adiponectin and its receptors in livers of morbidly obese patients with non-alcoholic fatty liver disease. J. Gastroenterol. Hepatol., 2009;24:233-237
45. Machado M., Cortez-Pinto H.: Non-alcoholic fatty liver disease and insulin resistance. Eur. J. Gastroenterol. Hepatol., 2005;17:823-826 (Pubitemid 41073319)
46. Magnusson I., Rothman D. L., Katz L. D., Shulman R. G., Shulman G. I.: Increased rate of gluconeogenesis in type II diabetes mellitus. A 13C nuclear magnetic resonance study. J. Clin. Invest., 1992;90:1323-1327
47. Mantzoros C. S.: The role of leptin in human obesity and disease: a review of current evidence. Ann. Intern. Med., 1999;130:671-680 (Pubitemid 29196202)
48. Marra F.: Leptin and liver fibroosis: a matter of fat. Gastroenterology, 2002;122:1529-1532 (Pubitemid 34465194)
49. Masaki T., Chiba S., Tatsukawa H., Yasuda T., Noguchi H., Seike M., Yoshimatsu H.: Adiponectin protects LPS-induced liver injury through modulation of TNF-a in KK-Ay obese mice. Hepatology, 2004;40:177-184 (Pubitemid 38868936)
50. McCullough A. J.: Pathopysiology of nonalcoholic steatohepatitis. J. Clin. Gastroenterol., 2006;40(Suppl. 1):S17-S29
51. Musso G., Gambino R., De Michieli F., Durazzo M., Pagano G., Cassader M.: Adiponectin gene polymorphisms modulate acute adiponectin response to dietary fat: possible pathogenetic role in NASH. Hepatology, 2008;47:1167-1177 (Pubitemid 351547903)
52. Musso G., Gambino R., Durazzo M., Biroli G., Carello M., Faga E., Pacini G., De Michieli F., Rabbione L., Premoli A., Cassader M., Pagano G.: Adipokines in NASH: postprandial lipid metabolism as a link between adiponectin and liver disease. Hepatology, 2005;42:1175-1183 (Pubitemid 43112685)
53. Nanji A. A., French S. W., Freeman J. B.: Serum alanine aminotransferase to aspartate aminotransferase ratio and degree of fatty liver in morbidly obese patients. Enzyme, 1986;36:266-269 (Pubitemid 17234838)
54. Nannipieri M., Cecchetti F., Anselmino M., Mancini E., Marchetti G., Bonotti A., Baldi S., Solito B., Giannetti M., Pinchera A., Santini F., Ferrannini E.: Pattern of expression of adiponectin receptors in human liver and its relation to nonalcoholic steatohepatitis. Obes. Surg., 2009;19:467-474
55. Neuschwander-Tetri B. A., Caldwell S. H.: Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology, 2003;37:1202-1219 (Pubitemid 36538699)
56. Olszanecka-Glinianowicz M., Zahorska-Markiewicz B., Janowska J., Kocełak P., Holecki M.: Zwiȩkszone stȩżenie interleukiny-6 (IL-6) u kobiet wia̧że siȩ z otyłoscia̧ a nie z insulinoopornoscia̧. Endokrynol. Pol., 2004;55:437-431
57. Olszanecka-Glinianowicz M., Zahorska-Markiewicz B., Janowska J., Żurakowski A.: Serum concentrations of nitric oxide, tumor necrosis factor (TNF)-a and TNF soluble receptors in women with overweight and obesity. Metabolism, 2004;53:1268-1273 (Pubitemid 39222086)
58. Olszanecka-Glinianowicz M., Zahorska-Markiewicz B., Kocełak P., Janowska J., Holecki M., Semik-Grabarczyk E.: Wpływ redukcji masy ciała na stȩżenie interleukiny-6 (IL-6) i insulinoopornosc. Endokrynol. Pol., 2006;57:131-135
59. Ouchi N., Kihara S., Arita Y., Okamoto Y., Maeda K., Kuriyama H., Hotta K., Nishida M., Takahashi M., Muraguchi M., Ohmoto Y., Nakamura T., Yamashita S., Funahashi T., Matsuzawa Y: Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-κB signaling through a cAMP-dependent pathway. Circulation, 2000;102:1296-1301
60. Pagano C., Soardo G., Pilon C., Milocco C., Basan L., Milan G., Donnini D., Faggian D., Mussap M., Plebani M., Avellini C., Federspil G., Sechi L. A., Vettor R.: Increased serum resistin in nonalcoholic fatty liver disease is related to liver disease severity and not to insulin resistance. J. Clin. Endocrinol. Metab., 2006;91:1081-1086 (Pubitemid 43357784)
61. Pajvani U. B., Du X., Combs T. P., Berg A. H., Rajala M. W., Schulthess T., Engel J., Brownlee M., Scherer P. E.: Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications for metabolic regulation and bioactivity. J. Biol. Chem., 2003;278:9073-9085 (Pubitemid 36800387)
62. Patel L., Buckels A. C., Kinghorn I. J., Murdock P. R., Holbrook J. D., Plumpton C., Macphee C. H., Smith S. A.: Resistin is expressed in human macrophages and directly regulated by PPARy activators. Biochem. Biophys. Res. Commun., 2003;300:472-476 (Pubitemid 38375833)
63. Pravenec M., Kazdová L., Landa V., Zidek V., Mlejnek P., Jansa P., Wang J., Qi N., Kurtz T. W.: Transgenic and recombinant resistin impair skeletal muscle glucose metabolism in the spontaneously hypertensive rat. J. Biol. Chem., 2003;278:45209-45215 (Pubitemid 37432654)
64. Rajala M. W., Obici S., Scherer P. E., Rossetti L.: Adipose-derived resistin and gut-derived resistin-like molecule-beta selectively impair insulin action on glucose production. J. Clin. Invest., 2003;111:225-230 (Pubitemid 36105921)
65. th ed., red. Feldman M., Friedman L. S., Brandt L. J., Saunders, Philadelphia, 2006, 1793-1805
66. Rothman D. L., Magnusson I., Katz L. D., Shulman R. G., Shulman G. I.: Quantitation of hepatic glycogenolysis and gluconeogenesis in fasting humans with 13C NMR. Science, 1991;254:573-576 (Pubitemid 21917377)
67. Sahai A., Malladi P., Pan X., Paul R., Melin-Aldana H., Green R. M., Whitington P. F.: Obese and diabetic db/db mice develop marked liver fibrosis in a model of nonalcoholic steatohepatitis: role of short-form leptin receptors and osteopontin. Am. J. Physiol. Gastrointest. Liver Physiol., 2004;287:G1035-G1043 (Pubitemid 39423696)
68. Saxena N. K., Ikeda K., Rockey D. C., Friedman S. L, Anania F. A.: Leptin in hepatic fibroosis: evidence for increased collagen production in stellate cells and lean littermates of ob/ob mice. Hepatology, 2002;35:762-771 (Pubitemid 34258369)
69. Seo J. A., Kim N. H., Park S. Y., Kim H. Y., Ryu O. H., Lee K. W., Lee J., Kim D. L., Choi K. M., Baik S. H., Choi D. S., Kim S. G.: Serum retinol-binding protein 4 levels are elevated in non-alcoholic fatty liver disease. Clin. Endocrinol., 2008;68:555-560 (Pubitemid 351388698)
70. Shimada M., Kawahara H., Ozaki K., Fukura M., Yano H., Tsuchishima M., Tsutsumi M., Takase S.: Usefulness of a combined evaluation of the serum adiponectin level, HOMA-IR, and serum type IV collagen 7S level to predict the early stage of nonalcoholic steatohepatitis. Am. J. Gastroenterol., 2007;102:1931-1938 (Pubitemid 47301507)
71. Shklyaev S., Aslanidi G., Tennant M., Prima V., Kohlbrenner E., Kroutov V., Campbell-Thompson M., Crawford J., Shek E. W., Scarpace P. J., Zolotukhin S.: Sustained peripheral expression of transgene adiponectin offsets the development of diet-induced obesity in rats. Proc. Natl. Acad. Sci. USA, 2003;100:14217-14222 (Pubitemid 37499217)
72. Silswal N., Singh A. K., Aruna B., Mukhopadhyay S., Ghosh S., Ehtesham N. Z.: Human resistin stimulates the pro-infammatory cytokines TNF-a and IL-12 in macrophages by NF-κB-dependent pathway. Biochem. Biophys. Res. Comm., 2005;334:1092-1101 (Pubitemid 41074686)
73. Takashima N., Tomoike H., Iwai N.: Retinol-binding protein 4 and insulin resistance. N. Engl. J. Med., 2006;355:1392
74. Tamori Y., Sakaue H., Kasuga M.: RBP4, an unexpected adipokine. Nat. Med., 2006;12:30-31 (Pubitemid 43050050)
75. Targher G., Bertolini L., Scala L., Poli F., Zenari L., Falezza G.: Decreased plasma adiponectin concentrations are closely associated with nonalcoholic hepatic steatosis in obese individuals. Clin. Endocrinol., 2004;61:700-703 (Pubitemid 40006789)
76. Thomas E. L., Hamilton G., Patel N., O'Dwyer R., Doré C. J., Goldin R. D., Bell J. D., Taylor-Robinson S. D.: Hepatic triglyceride content and its relation to body adiposity: a magnetic resonance imaging and proton magnetic resonance spectroscopy study. Gut, 2005;54:122-127 (Pubitemid 40007230)
77. Tokushige K., Takakura M., Tsuchiya-Matsushita N., Taniai M., Hashimoto E., Shiratori K.: Influence of TNF gene polymorphisms in Japanese patients with NASH and simple steatosis. J. Hepatol., 2007;46:1104-1110 (Pubitemid 46669735)
78. Tomita K., Oike Y., Teratani T., Taguchi T., Noguchi M., Suzuki T., Mizutani A., Yokoyama H., Irie R., Sumimoto H., Takayanagi A., Miyashita K., Akao M., Tabata M., Tamiya G., Ohkura T., Hibi T: Hepatic AdipoR2 signaling plays a protective role against progression of nonalcoholic steatohepatitis in mice. Hepatology, 2008;48:458-473
79. Tomita K., Tamiya G., Ando S., Ohsumi K., Chiyo T., Mizutani A., Kitamura N., Toda K., Kaneko T., Horie Y., Han J. Y, Kato S., Shimoda M., Oike Y., Tomizawa M., Makino S., Ohkura T., Saito H., Kumagai N., Nagata H., Ishii H., Hibi T: Tumour necrosis factor a signalling through activation of Kupffer cells plays an essential role in liver fibrosis of non-alcoholic steatohepatitis in mice. Gut, 2006;55:415-424 (Pubitemid 43268283)
80. Tsochatzis E., Papatheodoridis G. V., Archimandritis A. J.: The evolving role of leptin and adiponectin in chronic liver diseases. Am. J. Gastroenterol., 2006;101:2629-2640 (Pubitemid 44665263)
81. Tsochatzis E., Papatheodoridis G. V., Hadziyannis E., Georgiou A., Kafri G., Tiniakos D. G., Manesis E. K., Archimandritis A. J.: Serum adipokine levels in chronic liver diseases: association of resistin levels with fibroosis severity. Scand. J. Gastroenterol., 2008;43:1128-1136
82. Unger R. H.: Minireview: weapons of lean body mass destruction: the role of ectopic lipids in the metabolic syndrome. Endocrinology, 2003;144:5159-5165 (Pubitemid 37476041)
83. Unger R. H.: The physiology of cellular liporegulation. Annu. Rev. Physiol., 2003;65:333-347 (Pubitemid 38249157)
84. Unger R. H.: Lipid overload and overflow: metabolic trauma and the metabolic syndrome. Trends Endocrinol. Metab., 2003;14:398-403 (Pubitemid 37392211)
85. Unger R. H.: Lipotoxic diseases. Annu. Rev. Med., 2002;53:319-336 (Pubitemid 34177884)
86. Uysal K. T., Wiesbrock S. M., Marino M. W., Hotamisligil G. S.: Protection from obesity-induced insulin resistance in mice lacking TNF-α function. Nature, 1997;389:610-614 (Pubitemid 27446179)
87. Valenti L., Fracanzani A. L., Dongiovanni P., Santorelli G., Branchi A., Taioli E., Fiorelli G., Fargion S.: Tumor necrosis factor α promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease. Gastroenterology, 2002;122:274-280 (Pubitemid 34116980)
88. Varma V., Yao-Borengasser A., Rasouli N., Bodles A. M., Phanavanh B., Lee M. J., Starks T., Kern L. M., Spencer H. J. III, McGehee R. E. Jr., Fried S. K., Kern P. A.: Human visfatin expression: relationship to insulin sensitivity, intramyocellular lipids, and inflammation. J. Clin. Endocrinol. Metab., 2007;92:666-672
89. Wejstal R., Hansson G., Lindholm A., Norkrans G.: Persistent alanine aminotransferase elevation in healthy Swedish blood donors - mainly caused by obesity. Clin. Endocrinol., 2002;57:805-811
90. Wellen K. E., Hotamisligil G. S.: Obesity-induced infammatory changes in adipose tissue. J. Clin. Invest., 2003;112:1785-1788 (Pubitemid 38063699)
91. Wieckowska A., Papouchado B. G., Li Z., Lopez R., Zein N. N., Feldstein A. E.: Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis. Am. J. Gastroenterol., 2008;103:1372-1379 (Pubitemid 351813900)
92. Winkler G., Kiss S., Kesztheleyi L., Sápi Z., Ory I., Salamon F., Kovács M., Vargha P., Szekerez O., Speer G., Karádi I., Sikter M., Kaszás E., Dworak O., Gerö G., Cseh K.: Expression of tumor necrosis factor (TNF)-a protein in the subcutaneous and visceral adipose tissue in correlation with adipocyte cell volume, serum TNF-α, soluble serum TNF-receptor-2 concentrations and C-βeptide level. Eur. J. Endocrinol., 2003;149:129-135 (Pubitemid 36987155)
93. Wong V. W., Hui A. Y., Tsang S. W., Chan J. L., Tse A. M., Chan K. F., So W. Y., Cheng A. Y., Ng W. F., Wong G. L., Sung J. J., Chan H. L.: Metabolic and adipokine profile of Chinese patients with nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol., 2006;4:1154-1161 (Pubitemid 44311653)
94. Wulster-Radcliffe M. C., Ajuwon K. M., Wang J., Christian J. A., Spurlock M. E.: Adiponectin differentially regulates cytokines in porcine macrophages. Biochem. Biophys. Res. Commun., 2004;316:924-929 (Pubitemid 38368041)
95. Xu A., Wang Y., Keshaw H., Xu L. Y., Lam K. S., Cooper G. J.: The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J. Clin. Invest., 2003;112:91-100 (Pubitemid 38056380)
96. Yamauchi T., Hara K., Kubota N., Terauchi Y., Tobe K., Froguel P., Nagai R., Kadowaki T.: Dual roles of adiponectin/Acrp30 in vivo as an anti-diabetic and anti-atherogenic adipokine. Curr. Drug Targets Immune Endocr. Metabol. Disord., 2003;3:243-254
97. Yamauchi T., Kamon J., Ito Y., Tsuchida A., Yokomizo T., Kita S., Sugiyama T., Miyagishi M., Hara K., Tsunoda M., Murakami K., Ohteki T., Uchida S., Takekawa S., Waki H., Tsuno N. H., Shibata Y., Terauchi Y., Froguel P., Tobe K., Koyasu S., Taira K., Kitamura T., Shimizu T., Nagai R., Kadowaki T.: Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature, 2003;423:762-769 (Pubitemid 36735700)
98. Yang Q., Graham T. E., Mody N., Preitner F., Peroni O. D., Zabolotny J. M., Kotani K., Quadro L., Kahn B. B.: Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature, 2005;436:356-362 (Pubitemid 41065039)
99. Yokota T., Oritani K., Takahashi I., Ishikawa J., Matsuyama A., Ouchi N., Kihara S., Funahashi T., Tenner A. J., Tomiyama Y., Matsuzawa Y.: Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood, 2000;96:1723-1732 (Pubitemid 30661055)
100. You M., Considine R. V., Leone T. C., Kelly D. P., Crabb D. W.: Role of adiponectin in the protective action of dietary saturated fat against alcoholic fatty liver in mice. Hepatology, 2005;42:568-577 (Pubitemid 41233649)
101. Younossi Z. M., Jarrar M., Nugent C., Randhawa M., Afendy M., Stepanova M., Rafiq N., Goodman Z., Chandhoke V., Baranova A.: A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH). Obes. Surg., 2008;18:1430-1437
102. Zahorska-Markiewicz B., Janowska J., Olszanecka-Glinianowicz M., Zurakowski A.: Serum concentration of TNF-α and soluble TNF-a receptors in obesity. Int. J. Obes. Relat. Metab. Disord., 2000;24:1392-1395
103. Zahorska-Markiewicz B., Olszanecka-Glinianowicz M., Janowska J., Kocełak P., Semik-Grabarczyk E., Holecki M., Da̧browski P., Skorupa A.: Serum concentration of visfatin in obese women. Metabolism, 2007;56:1131-1134 (Pubitemid 47021180)